Article Text

Download PDFPDF

484 BALB/c-hVTCN1 – an ideal mouse model for evaluating the efficacy and safety of human VTCN1 inhibitors
  1. Huiyi Wang1,
  2. Jialu Fan1,
  3. Lingyu Song1,
  4. Shiying Guo1,
  5. Xing Liu1,
  6. Shuai Li1,
  7. Santi Chen2,
  8. Jing Zhao1,
  9. Xiang Gao1 and
  10. Cunxiang Ju1
  1. 1GemPharmatech Co., Ltd, Nanjing, Jiangsu, China
  2. 2GemPharmatech, Wilmington, DE, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background VTCN1, also known as B7-H4, is a protein that is expressed on the surface of certain cells, including tumor cells and immune cells. It belongs to the B7 family of immune checkpoint molecules, which play a crucial role in regulating the immune response. Immune checkpoint molecules can either promote or suppress immune responses, and their dysregulation can contribute to immune evasion by cancer cells.

Methods To evaluate the efficacy and safety of human VTCN1 inhibitors in an immunocompetent mouse model, we developed a humanized VTCN1 mouse model on BALB/c background (BALB/c-hVTCN1), using the CRISPER-CAS9 technology to replace the mouse VTCN1 (mVTCN1) extracellular IgV domain (not including the LQLLNS sequence) of BALB/c mice with the corresponding human VTCN1 (hVTCN1) fragments. In BALB/c-hVTCN1 mouse model, human VTCN1 could be detected in several tissues including heart, lung, breast, liver, kidney, etc. Also, there was no difference in blood leukocyte subpopulations in BALB/c and BALB/c-hVTCN1 mice.

Results Gempharmatech has evaluated the efficacy of VTCN1 inhibitors in preclinical models involves assessing their impact on tumor growth, tumor weight and immune cell infiltration, which demonstrated VTCN1 inhibitors could significantly inhibit tumor growth in BALB/c-hVTCN1 tumor bearing mouse model.

Conclusions In summary, the VTCN1 humanized mouse model can be used in the preclinical evaluation of mono or combined immune checkpoint blockade with anti-human VTCN1 therapy.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.